SE9203594D0 - Laekemedel i dispersa system - Google Patents

Laekemedel i dispersa system

Info

Publication number
SE9203594D0
SE9203594D0 SE9203594A SE9203594A SE9203594D0 SE 9203594 D0 SE9203594 D0 SE 9203594D0 SE 9203594 A SE9203594 A SE 9203594A SE 9203594 A SE9203594 A SE 9203594A SE 9203594 D0 SE9203594 D0 SE 9203594D0
Authority
SE
Sweden
Prior art keywords
pct
date
dispersa
medicinal product
sec
Prior art date
Application number
SE9203594A
Other languages
English (en)
Swedish (sv)
Inventor
Christer Nystroem
Lennart Paalzow
Sten-Magnus Aquilonius
Original Assignee
Christer Nystroem
Lennart Paalzow
Sten Magnus Aquilonius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christer Nystroem, Lennart Paalzow, Sten Magnus Aquilonius filed Critical Christer Nystroem
Priority to SE9203594A priority Critical patent/SE9203594D0/xx
Publication of SE9203594D0 publication Critical patent/SE9203594D0/xx
Priority to ES94901148.0T priority patent/ES2137350T7/es
Priority to DE200512000021 priority patent/DE122005000021I1/de
Priority to PCT/SE1993/001029 priority patent/WO1994012153A1/en
Priority to US08/446,799 priority patent/US5635213A/en
Priority to AU55836/94A priority patent/AU688290B2/en
Priority to EP94901148.0A priority patent/EP0670713B3/en
Priority to DE69326350.4T priority patent/DE69326350T3/de
Priority to CA002150464A priority patent/CA2150464C/en
Priority to NZ258276A priority patent/NZ258276A/en
Priority to JP51306094A priority patent/JP3661703B2/ja
Priority to DK94901148T priority patent/DK0670713T3/da
Priority to AT94901148T priority patent/ATE184191T3/de
Priority to GR990403081T priority patent/GR3031988T3/el
Priority to FR04C0024C priority patent/FR04C0024I2/fr
Priority to NL300169C priority patent/NL300169I1/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9203594A 1992-11-30 1992-11-30 Laekemedel i dispersa system SE9203594D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
AT94901148T ATE184191T3 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung
EP94901148.0A EP0670713B3 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation
CA002150464A CA2150464C (en) 1992-11-30 1993-11-29 A pharmaceutical formulation for intraduodenal administration
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation
US08/446,799 US5635213A (en) 1992-11-30 1993-11-29 Pharmaceutical formulation
AU55836/94A AU688290B2 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation
ES94901148.0T ES2137350T7 (es) 1992-11-30 1993-11-29 Formulación farmacéutica
DE69326350.4T DE69326350T3 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung
DE200512000021 DE122005000021I1 (de) 1992-11-30 1993-11-29 Pharmazeutische formulierung
NZ258276A NZ258276A (en) 1992-11-30 1993-11-29 Pharmaceutical dispersion for intraduodenal administration
JP51306094A JP3661703B2 (ja) 1992-11-30 1993-11-29 製薬学的製剤
DK94901148T DK0670713T3 (da) 1992-11-30 1993-11-29 Farmaceutisk formulering
GR990403081T GR3031988T3 (en) 1992-11-30 1999-11-30 A pharmaceutical formulation.
FR04C0024C FR04C0024I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-11-30 2004-10-22
NL300169C NL300169I1 (nl) 1992-11-30 2005-01-03 Farmaceutische formulering.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system

Publications (1)

Publication Number Publication Date
SE9203594D0 true SE9203594D0 (sv) 1992-11-30

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system

Country Status (15)

Country Link
US (1) US5635213A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0670713B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3661703B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE184191T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU688290B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2150464C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE122005000021I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0670713T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2137350T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR04C0024I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3031988T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300169I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ258276A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE9203594D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994012153A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2007138086A1 (en) * 2006-05-31 2007-12-06 Solvay Pharmaceuticals Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10335540B2 (en) 2012-04-17 2019-07-02 Micrel Medical Devices S.A. Pharmaceutical blend infusion thereof and Parkinson's disease monitoring system
HUE052857T2 (hu) 2014-09-04 2021-05-28 Lobsor Pharmaceuticals Ab Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
UA120437C2 (uk) 2014-10-21 2019-12-10 Еббві Інк. Проліки карбідопа і l-dopa і їхнє застосування для лікування хвороби паркінсона
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
EP4278996A3 (en) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Implant placement systems
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN109715139A (zh) * 2016-07-20 2019-05-03 艾伯维公司 左旋多巴和卡比多巴肠凝胶以及使用方法
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2019166322A1 (en) 2018-03-02 2019-09-06 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US11547689B2 (en) 2018-03-23 2023-01-10 Intrance International Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
DE69326350T2 (de) 2000-01-27
JP3661703B2 (ja) 2005-06-22
JPH08504764A (ja) 1996-05-21
EP0670713A1 (en) 1995-09-13
ES2137350T3 (es) 1999-12-16
DE122005000021I1 (de) 2006-02-23
AU688290B2 (en) 1998-03-12
EP0670713B1 (en) 1999-09-08
DE69326350D1 (de) 1999-10-14
ATE184191T3 (de) 1999-09-15
CA2150464A1 (en) 1994-06-09
ES2137350T7 (es) 2017-11-13
FR04C0024I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-12-31
DE69326350T3 (de) 2018-01-11
NZ258276A (en) 1996-09-25
AU5583694A (en) 1994-06-22
US5635213A (en) 1997-06-03
FR04C0024I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2004-03-12
WO1994012153A1 (en) 1994-06-09
EP0670713B3 (en) 2016-10-05
DK0670713T3 (da) 2000-03-20
CA2150464C (en) 2002-02-05
NL300169I1 (nl) 2005-03-01
GR3031988T3 (en) 2000-03-31

Similar Documents

Publication Publication Date Title
SE9203594D0 (sv) Laekemedel i dispersa system
ES2115945T3 (es) Preparaciones topicas cosmeticas y medicinales.
DE69224294D1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
DE69106501D1 (de) Osmotisches dosiersystem zur verabreichung von flüssigen arzneimitteln.
ITMI922192A1 (it) Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
TW347339B (en) Oral delivery of discrete units
EP0788346A4 (en) EMULSION DRUG DELIVERY SYSTEMS
ES2162867T3 (es) Metodo de fabricacion de formas de dosificacion de farmacos liofilizados.
FI970788A0 (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
IE873125L (en) Benzimidazole derivatives
FR2692168B1 (fr) Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
SE8305485D0 (sv) Galenic compositions comprising calcitonin and their use
AR008355A1 (es) COMPOSICIoN FARMACÉUTICA PARA ADMINISTRACIoN ORAL, USO, CREMA FARMACEUTICA PARA ADMINISTRACIoN TOPICA Y SUSPENSIoN LIQUIDA PARA ADMINISTRACIoN ORAL.
ITMI931326A1 (it) Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico
ES2196632T3 (es) Complejo entre carragenina y un medicamento soluble en agua con una granulometria especifica y composiciones farmaceuticas de liberacion controlada relativa.
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
DE69323202D1 (de) Ophthalmologische zubereitungen
MY102411A (en) Nasal solutions
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
HRP20020332B1 (hr) Oralne otopine koje sadrže galantamin i sladilo
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso
DE59408645D1 (de) Lactulose-pastillen